Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jun Teishima

Showing results (181-190 of 240) with videos related to

Pageof 24
Sort By:
Anticancer Research|April 3, 2020
PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell CarcinomaYohei Sekino, Takeshi Hagura, Xiangrui Han, et al.
International Journal of Clinical Oncology|May 27, 2026
Comparison of effectiveness and safety of pembrolizumab plus lenvatinib versus nivolumab plus cabozantinib for metastatic renal cell carcinoma: a real-world studyTaisuke Tobe, Jun Teishima, Yoshie Mita, et al.
Oncology Letters|July 12, 2014
Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapyJun Teishima, Kohei Kobatake, Tetsutaro Hayashi, et al.
Cancer Medicine|July 9, 2021
Overexpression of claspin promotes docetaxel resistance and is associated with prostate-specific antigen recurrence in prostate cancerTakashi Babasaki, Kazuhiro Sentani, Yohei Sekino, et al.
Oncology Letters|October 9, 2023
The impact of primary region resection on the therapeutic outcome of combination regimens for metastatic renal cell carcinomaJun Teishima, Takuto Hara, Taisuke Tobe, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|February 6, 2024
Therapeutic outcome of combination therapy using immune-checkpoint inhibitors and tyrosine kinase inhibitors for metastatic non-clear-cell renal cell carcinomaJun Teishima, Takuto Hara, Taisuke Tobe, et al.
International Cancer Conference Journal|June 26, 2020
Renal metastasis from primary hepatocellular carcinoma: a case reportRyoken Yamanaka, Yohei Sekino, Takashi Babasaki, et al.
Urologic Oncology|August 6, 2017
The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitorJun Teishima, Kohei Kobatake, Shunsuke Shinmei, et al.
Frontiers in Oncology|December 26, 2022
Complexity in radiological morphology predicts worse prognosis and is associated with an increase in proteasome component levels in clear cell renal cell carcinomaKohei Kobatake, Kenichiro Ikeda, Jun Teishima, et al.
Urologic Oncology|July 19, 2022
Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitorKazuma Yukihiro, Jun Teishima, Keisuke Goto, et al.
Pageof 24

Showing results (181-190 of 240) with videos related to

Sort By:
Pageof 24
Anticancer Research|April 3, 2020
PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell CarcinomaYohei Sekino, Takeshi Hagura, Xiangrui Han, et al.
International Journal of Clinical Oncology|May 27, 2026
Comparison of effectiveness and safety of pembrolizumab plus lenvatinib versus nivolumab plus cabozantinib for metastatic renal cell carcinoma: a real-world studyTaisuke Tobe, Jun Teishima, Yoshie Mita, et al.
Oncology Letters|July 12, 2014
Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapyJun Teishima, Kohei Kobatake, Tetsutaro Hayashi, et al.
Cancer Medicine|July 9, 2021
Overexpression of claspin promotes docetaxel resistance and is associated with prostate-specific antigen recurrence in prostate cancerTakashi Babasaki, Kazuhiro Sentani, Yohei Sekino, et al.
Oncology Letters|October 9, 2023
The impact of primary region resection on the therapeutic outcome of combination regimens for metastatic renal cell carcinomaJun Teishima, Takuto Hara, Taisuke Tobe, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|February 6, 2024
Therapeutic outcome of combination therapy using immune-checkpoint inhibitors and tyrosine kinase inhibitors for metastatic non-clear-cell renal cell carcinomaJun Teishima, Takuto Hara, Taisuke Tobe, et al.
International Cancer Conference Journal|June 26, 2020
Renal metastasis from primary hepatocellular carcinoma: a case reportRyoken Yamanaka, Yohei Sekino, Takashi Babasaki, et al.
Urologic Oncology|August 6, 2017
The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitorJun Teishima, Kohei Kobatake, Shunsuke Shinmei, et al.
Frontiers in Oncology|December 26, 2022
Complexity in radiological morphology predicts worse prognosis and is associated with an increase in proteasome component levels in clear cell renal cell carcinomaKohei Kobatake, Kenichiro Ikeda, Jun Teishima, et al.
Urologic Oncology|July 19, 2022
Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitorKazuma Yukihiro, Jun Teishima, Keisuke Goto, et al.
Pageof 24